Kura Oncology Inc at Barclays Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Peter Lawson - Barclays - Analyst : And then I guess kind of first question is around the updates that we're going to see in the combination therapy and kind of what we should expect to see in that kind of mid '24 update in combinations and then in the oh seven truck?

Question: Peter Lawson - Barclays - Analyst : if you know, you've been reading the questions the pivots to like frontline or removing the restrictions as fluid. Would that be? Do you have to go back to the FDA with that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 14, 2024 / 1:00PM, KURA.OQ - Kura Oncology Inc at Barclays Global Healthcare Conference

Question: Peter Lawson - Barclays - Analyst : Do you think, I guess you've probably answered that question with that comment, but, do you think we'll have different doses different.

Question: Peter Lawson - Barclays - Analyst : Got it. Thank you. And over the I guess, the last year or so, we've heard about resistance, mutations and those questions kind of ebb and flow.

Question: Peter Lawson - Barclays - Analyst : You seen those emerge as your (inaudible) resistant to resistant mutations.

Question: Peter Lawson - Barclays - Analyst : Got it. And I guess with the NPM1 mutation this often and other mutations there, does that cloud the use of an NPM1 menin inhibitor in that space?

Question: Peter Lawson - Barclays - Analyst : Look when we see an update or the initial data around 008?

Question: Peter Lawson - Barclays - Analyst : Great. Thank you so much. Then you touched upon this the enrollment's going well, could have overenrolled once your pivotal trial?

Question: Peter Lawson - Barclays - Analyst : (inaudible) any of the conversion data consistently being generated from cannot be rolled over into some kind of pivotal trial?

Question: Peter Lawson - Barclays - Analyst : Got it. The expansion opportunities outside blood cancers. Where do we -- when do we get kind of more details, (multiple speakers) --

Question: Peter Lawson - Barclays - Analyst : Okay. So what's clin trials or you will (multiple speakers)

Question: Peter Lawson - Barclays - Analyst : Perfect. Thank you so much (inaudible)